Bisphosphonates and jaw osteonecrosis: The UAMS experience

被引:35
作者
Clarke, Brett M.
Boyette, Jennings
Vural, Emre
Suen, James Y.
Anaissie, Elias J.
Stack, Brendan C., Jr.
机构
[1] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
关键词
D O I
10.1016/j.otohns.2006.11.008
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
BACKGROUND: Over the past year at least 10 case series and several case reports on osteonecrosis of the jaw (ONJ) have been published with most found in the oral surgery literature. This clinical entity is largely unknown to head and neck surgeons. METHODS: Retrospective chart review. RESULTS: A total of 479 charts were reviewed, identifying 25 individuals meeting inclusion criteria. Mean age was 63.4 (standard deviation, 9.9) years; 40% were female. Multiple myeloma was the most common comorbidity. Twenty-five patients were treated with bisphosphonates for 4.4 years (range, 1 to 8 years); most commonly pamidronate before ONJ diagnosis. Forty-two percent (10) took steroids within the month before diagnosis. Fifty-two percent (11) underwent dental work before developing ONJ. CONCLUSION: These data reflect the importance of awareness of the possibility of ONJ with bisphosphonate therapy. (c) 2007 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
引用
收藏
页码:396 / 400
页数:5
相关论文
共 24 条
[1]  
[Anonymous], 2005, ONC DRUGS ADV COMM M
[2]  
Assouline-Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
[3]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[4]   Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: Paradoxical complication of treatment of bone lesions in multiple myeloma patients [J].
Capalbo, S ;
Delia, M ;
Diomede, D ;
Dargenio, M ;
Chiefa, A ;
Favia, G ;
Liso, V .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2006, 83 (05) :439-442
[5]  
Carneiro E, 2006, AM J NEURORADIOL, V27, P1096
[6]  
Damato K, 2005, EXPERT PANEL RECOMME
[7]  
Durie BGM, 2005, NEW ENGL J MED, V353, P99
[8]   Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates [J].
Farrugia, MC ;
Summerlin, DJ ;
Krowiak, E ;
Huntley, T ;
Freeman, S ;
Borrowdale, R ;
Tomich, C .
LARYNGOSCOPE, 2006, 116 (01) :115-120
[9]   Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century? [J].
Hellstein, JW ;
Marek, CL .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2005, 63 (05) :682-689
[10]  
Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349